Table 1.

Patient characteristics and treatment outcome

Patient	Age at diagnosis (years)	Grade	Number lesions	Age BV treatment (years)	KPS	Prior therapies	BV partner	Months of BV treatment	Reason BV discontinued	Time to progression (months)
1	30	I	2	45	80	Resection × 3, tamoxifen/RT, imatinib/hydroxyurea, SRS, octreotide/celebrex	Etoposide	29.5	PD	29.5
2	44	III	1	53	90	Resection × 3, temozolomide/RT, octreotide, imatinib/hydroxyurea, 5-day temozolomide	Etoposide, sirolimus	5.9	PD	5.9
3	51	II	1	57	80	Resection × 3, hydroxyurea, SRS, imatinib, pasireotide	Etoposide	7.0	Ongoing	None
4	28	III	1	43	90	Resection × 2, RT, SRS, 5-day temozolomide	Etoposide	19.4	PD	19.4
5	52	II	1	54	80	Resection × 2, temozolomide/RT, SRS	Etoposide	2.5	Compliance	None
6	46	II	1	54	80	Resection × 1, RT, SRS	Temozolomide (daily)	10.0	Ongoing	None
7	53	I	1	57	90	Resection × 2, imatinib/hydroxyurea, daily temozolomide	None	13.3	PD	13.3
8	47	III	3	52	80	Resection × 2, temozolomide/RT, etoposide/5-day temozolomide, imatinib/hydroxyurea	None	17.1	PD	17.1
9	30	I	4	50	70	Resection × 2, RT, octreotide	Temozolomide (5-day)	9.2	PD	9.2
10	65	II	1	66	70	Resection × 2, RT/temozolomide	None	7.0	Ongoing	None
11	42	Unknown	1	59	80	Resection × 2; RT; SRS	None	7.0	Toxicity	None
12	19	I	1	20	90	Resection; SRS; RT	Temozolomide (5-day)	8.0	Ongoing	None
13	37	I	3	51	60	Resection; imatinib/hydroxyurea; temozolomide	Etoposide	0.5	Toxicity	None
14	77	II	1	79	90	Resection	Temozolomide (5-day)	0.5	Toxicity	None

BV bevacizumab, KPS Karnofsky performance status, NA not applicable, PD progressive disease, RT radiation therapy, SRS stereotactic radiosurgery